Role of pharmacist in End-Stage Renal Disease
Phase 2
- Conditions
- Health Condition 1: N186- End stage renal disease
- Registration Number
- CTRI/2023/10/058396
- Lead Sponsor
- College of Pharmacy,SRIPMS
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patient undergoing hemodialysis and patient signing patient consent form.
Exclusion Criteria
Patient who have previously failed renal transplantation , who have ESRD of inflammatory cause(lupus, vasculitis, collagenopathies) , who had intake of probiotics,prebiotics in last 3 months, who have any medical condition affecting intestinal absorption(inflammatory bowel disease,short bowel syndrome, bariatric surgery) or severe dysmotility, who are taking any alternative medicine other than allopathic medicine, who are frail , who are treated with antibiotics , with severe malnutrition and with severe other diseases.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change of uremic toxin from baseline to 6th week and 12th week. <br/ ><br>Measurement of serum concentrations of the uremic toxin indoxyl sulphate (mg/dL) by means of HPLC technique.Timepoint: Change of uremic toxin from baseline to 6th week and 12th week. <br/ ><br>Measurement of serum concentrations of the uremic toxin indoxyl sulphate (mg/dL) by means of HPLC technique.
- Secondary Outcome Measures
Name Time Method Change in gastrointestinal symptoms from baseline to 3rd and 6th month. <br/ ><br>Measurement of appetite and frequency and severity of gastrointestinal symptoms(nausea,vomiting,bloating,diarrhea,constipation)by means of GSRS questionnaire. <br/ ><br>Change in serum creatinine level and eGFR rate from baseline to 3rd and 6th monthTimepoint: baseline , 3rd ,6th month